Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate
Open Access
- 1 September 2003
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (5) , e57-e62
- https://doi.org/10.1086/376991
Abstract
Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.Keywords
This publication has 18 references indexed in Scilit:
- Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosineAIDS, 2001
- Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppressionAIDS, 2001
- Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugsAIDS, 2001
- Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfectionThe Lancet, 2001
- Acute pancreatitis in human immunodeficiency virus–infected patients: a reviewThe American Journal of Medicine, 1999
- Acute pancreatitis in HIV-seropositive patients: A case control study of 44 patientsThe American Journal of Medicine, 1995
- Rates and Risk Factors for Adverse Events Associated with Didanosine in the Expanded Access ProgramClinical Infectious Diseases, 1994
- The Didanosine Expanded Access Program: Safety AnalysisClinical Infectious Diseases, 1993
- A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- Pancreatitis in pediatric human immunodeficiency virus infectionThe Journal of Pediatrics, 1992